Lucira Health, Inc. (NASDAQ:LHDX – Get Rating) was the target of a significant drop in short interest in May. As of May 15th, there was short interest totalling 261,000 shares, a drop of 15.9% from the April 30th total of 310,300 shares. Approximately 0.9% of the company’s stock are sold short. Based on an average trading volume of 105,500 shares, the days-to-cover ratio is currently 2.5 days.
Several equities research analysts have weighed in on LHDX shares. Zacks Investment Research downgraded Lucira Health from a “buy” rating to a “hold” rating in a report on Thursday, May 12th. Lifesci Capital raised Lucira Health from a “market perform” rating to an “outperform” rating in a report on Tuesday, March 22nd.
In other Lucira Health news, insider Erik T. Engelson purchased 30,000 shares of the stock in a transaction on Tuesday, March 15th. The stock was acquired at an average price of $3.00 per share, with a total value of $90,000.00. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link.
Shares of Lucira Health stock traded down $0.13 on Wednesday, reaching $1.84. 684 shares of the stock were exchanged, compared to its average volume of 113,367. The company has a current ratio of 3.72, a quick ratio of 2.67 and a debt-to-equity ratio of 0.14. Lucira Health has a twelve month low of $1.90 and a twelve month high of $11.10. The business has a 50 day moving average price of $2.94 and a two-hundred day moving average price of $4.72.
Lucira Health (NASDAQ:LHDX – Get Rating) last released its earnings results on Thursday, May 12th. The company reported $0.40 EPS for the quarter, topping analysts’ consensus estimates of ($0.08) by $0.48. Lucira Health had a negative return on equity of 10.14% and a negative net margin of 21.47%. During the same quarter in the prior year, the business earned ($0.54) earnings per share. Sell-side analysts anticipate that Lucira Health will post 0.29 EPS for the current year.
Lucira Health Company Profile (Get Rating)
Lucira Health, Inc, a medical technology company, focuses on the development and commercialization of infectious disease test kits. It develops a testing platform that produces molecular testing services. The company offers LUCIRA COVID-19 All-In-One Test Kit, a COVID-19 test kit; and develops influenza A and B viruses test kits.
- Get a free copy of the StockNews.com research report on Lucira Health (LHDX)
- The Analysts Like The Fit Of Victoria’s Secret & Co
- Ambarella Is A Buy For Patient Investors
- Don’t Bet On A Big Rebound For Salesforce.com Stock
- 3 Specialty Retailers with Special Upside
- Is Roku (NASDAQ: ROKU) Bottoming Out?
Want More Great Investing Ideas?
- Bear Market Game Plan!
- The 10 Best Stocks to Own in 2022
- 7 Stocks to Buy and Hold Forever
- 3 Stocks to DOUBLE This Year
Receive News & Ratings for Lucira Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Lucira Health and related companies with MarketBeat.com's FREE daily email newsletter.